文献速递肾癌与肾肿瘤

减瘤性肾切除术在转移性乳头状肾细胞癌中的应用:IMDC数据库结果

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
PubMed 文献 · Eur Urol Oncol · 2019-04-05

基于IMDC数据库的回顾性分析纳入647例乳头状转移性肾细胞癌患者,其中353例为同步转移,109例接受减瘤性肾切除术(CN)而244例未接受。CN组中位总生存(OS)为16.3个月,显著优于未CN组的8.6个月(p<0.0001);校正IMDC风险因素后,CN与死亡风险降低相关(HR 0.62,95%CI 0.45-0.85;p=0.0031)。

要点

  • 在同步转移性乳头状肾细胞癌中,减瘤性肾切除术与更好的总生存相关。
  • 校正IMDC个体风险因素后,CN组死亡风险显著降低(HR 0.62)。
  • 该人群罕见,随机临床试验可能难以开展,需谨慎选择CN候选者。

核心结论

  • 在转移性乳头状肾细胞癌患者中,减瘤性肾切除术与未行CN相比,校正风险标准后与更好的生存相关。
  • 选择合适的CN候选患者至关重要。

研究设计与样本

  • 利用国际转移性肾细胞癌数据库联盟(IMDC)数据库进行的回顾性分析。
  • 共识别647例乳头状转移性肾细胞癌患者,其中353例为同步转移性疾病。
  • 同步转移患者中,109例接受减瘤性肾切除术,244例未接受。

主要发现

  • 整个队列的中位随访时间为57.1个月(95%CI 32.9-77.8)。
  • 整个队列从一线靶向治疗开始的中位总生存(OS)为13.2个月(95%CI 12.0-16.1)。
  • CN组的中位OS为16.3个月,未CN组为8.6个月(p<0.0001)。
  • 校正个体IMDC风险因素后,CN的死亡风险比(HR)为0.62(95%CI 0.45-0.85;p=0.0031)。

关键数值与推荐

  • 同步转移性乳头状肾细胞癌患者中,CN组中位OS 16.3个月 vs 未CN组8.6个月(p<0.0001)。
  • 校正IMDC风险因素后,CN与死亡风险降低相关(HR 0.62,95%CI 0.45-0.85;p=0.0031)。

临床怎么用

  • 对于同步转移性乳头状肾细胞癌患者,在综合评估IMDC风险因素后,可考虑减瘤性肾切除术以改善生存。
  • 需个体化选择适合CN的候选患者。

局限性

  • 分析为回顾性 nature。
  • 该人群罕见,可能无法开展临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is evidence that cytoreductive nephrectomy (CN) may be beneficial in metastatic renal cell carcinoma (mRCC). This has been studied predominantly in clear-cell RCC, with more limited data on the role of CN in patients with papillary histology. OBJECTIVE: To determine the benefit of CN in synchronous metastatic papillary RCC. DESIGN, SETTING, AND PARTICIPANTS: Using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) database, a retrospective analysis was performed for patients with papillary mRCC treated with or without CN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Median overall survival (OS) and progression-free survival (PFS) were determined for both patient groups. Cox regression analysis was performed to control for imbalances in individual IMDC risk factors. RESULTS AND LIMITATIONS: In total, 647 patients with papillary mRCC were identified, of whom 353 had synchronous metastatic disease. Of these, 109 patients were treated with CN and 244 were not. The median follow-up was 57.1mo (95% confidence interval [CI] 32.9-77.8) and the OS from the start of first-line targeted therapy for the entire cohort was 13.2mo (95% CI 12.0-16.1). Median OS for patients with CN was 16.3mo, compared to 8.6mo (p<0.0001) in the no-CN group. When adjusted for individual IMDC risk factors, the hazard ratio (HR) of death for CN was 0.62 (95% CI 0.45-0.85; p=0.0031). Limitations include the retrospective nature of the analysis. CONCLUSIONS: The use of CN in patients with mRCC and papillary histology appears to be associated with better survival compared to no CN after adjustment for risk criteria. Selection of appropriate candidates for CN is crucial. A clinical trial in this rare population may not be possible. PATIENT SUMMARY: In a population of patients with advanced papillary kidney cancer, we found that surgical removal of the primary kidney tumor was associated with better overall survival.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Graham J, Wells JC, Donskov F, et al. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2019. PMID: 31411994. doi:10.1016/j.euo.2019.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。